Boehringer Ingelheim Corporation Release: New Data Analyses Show Consistent Efficacy And Safety Profile Of Pradaxa® In Broad Range Of Patients With Acute Deep Vein Thrombosis Or Pulmonary Embolism
Published: Dec 10, 2013
INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only. New data analyses show that the positive treatment effect (efficacy and safety profile) of Pradaxa® (dabigatran etexilate) 150mg twice daily was consistent in a wide range of patients with acute deep vein thrombosis (DVT), a blood clot in the leg veins, or pulmonary embolism (PE), a blood clot in the lung, regardless of age, renal function, simultaneous use of non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose acetylsalicylic acid (ASA), or the presence of cancer.1-4 These new findings from the pooled safety analysis of the RE-COVER™ and RE-COVER™ II phase III clinical trials were presented this week during the American Society of Hematology Annual Meeting, New Orleans, USA.1-4
Help employers find you! Check out all the jobs and post your resume.